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ABSTRACT
Introduction: Platin-induced peripheral neu-
ropathy (PIPN) is a common cause of PN in
cancer patients. The aim of this paper is to sys-
tematically review the current literature
regarding PIPN, with a particular focus on epi-
demiological and clinical characteristics of
painful PIPN, and to discuss relevant manage-
ment strategies.
Methods: A systematic computer-based litera-
ture search was conducted on the PubMed
database.
Results: This search strategy resulted in the
identification of 353 articles. After the eligibility
assessment, 282 articles were excluded. An addi-
tional 24 papers were identified by scanning the
reference lists. In total, 95 papers met the inclu-
sion criteria and were used for this review. The
prevalence of neuropathic symptoms due to acute
toxicity of oxaliplatin was estimated at 84.6%,
whereas PN established after chemotherapy with
platins was estimated at 74.9%. Specifically
regarding pain, the reported prevalence of pain
due to acute toxicity of oxaliplatin was estimated
at 55.6%, whereas the reported prevalence of
chronic peripheral neuropathic pain in PIPN was
estimated at 49.2%.
Conclusion: Peripheral neuropathy is a com-
mon complication in patients receiving platins
and can be particularly painful. There is signif-
icant heterogeneity among studies regarding
the method for diagnosing peripheral neu-
ropathy. Nerve conduction studies are the gold
standard and should be performed in patients
receiving platins and complaining of neuro-
pathic symptoms post-treatment.
Keywords: Cancer; Chemotherapy; Pain;
Platin; Polyneuropathy
INTRODUCTION
The term ‘‘peripheral neuropathy’’ (PN) refers to
various disorders of the peripheral nervous sys-
tem, including single and multiple (asymmet-
ric) mononeuropathies, symmetrical
involvement of many nerves (polyneuropathy),
or the sole involvement of the dorsal root gan-
glia [1, 2].
PN is very prevalent in cancer patients [3]
and can be a direct or an indirect complication
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of cancer or cancer-related treatment, a pre-ex-
isting comorbidity not related to cancer, or part
of a paraneoplastic syndrome [4–7].
The vast majority of chemotherapy-induced
PN (CIPN) is caused by neurotoxic chemother-
apy schemes, with platins (cisplatin, oxali-
platin, carboplatin) constituting the leading
source of treatment-induced PN in cancer.
Contrary to the perception that painful neu-
ropathies are largely caused by diabetes, other
forms of PN can be particularly painful, leading
to poor quality of life [2]. Therefore, platin-in-
duced peripheral neuropathy (PIPN) should be
considered a major cause of pain in cancer
patients [8].
The aim of this paper is to systematically
review the epidemiological and clinical charac-
teristics of painful PIPN and provide an over-
view of relevant management strategies.
METHODS
Literature Search Strategy
A systematic computer-based literature search
was conducted August 15, 2017, on the PubMed
database. For the search, we used three Medical
Subject Headings (MeSH) terms in either the
title or abstract, as follows: (1) ‘‘neuronopathy’’
or ‘‘ganglionopathy’’ or ‘‘neuropathy’’ or
‘‘polyneuropathy’’; (2) ‘‘pain’’ or ‘‘painful’’; (3)
‘‘chemotherapy’’ or ‘‘platin’’ or ‘‘platins’’ or ‘‘ox-
aliplatin’’ or ‘‘cisplatin’’. Articles were limited to
English language, species to human, and with
full text available. We also perused the reference
lists of the papers in order to identify papers not
found through the search strategy.
Inclusion and Exclusion Criteria
Articles eligible for inclusion in the review were
required to meet the following criteria:
1. Involved case series with platin-induced PN.
2. Studied human adult subjects.
The following were excluded:
1. Book chapters, reviews, letters to the editor,
and editorials that did not provide new
data.
2. Papers providing incomplete clinical or
neurophysiological data about the single
cases/case series.
Data Extraction
Data were extracted from each study in a
structured coding scheme using Microsoft
Excel, and included information on the article
identification, year of publication, evaluation
period, total number of subjects, gender, age,
presence of pain in general, presence of pain
secondary to the neuropathy, neurophysiologi-
cal type of neuropathy, course of symptoms,
type of cancer, and type of platin. We also col-
lected information about the time point of
diagnosis in each study, and whether they
referred to acute toxicity or cumulative effect
after completion of all cycles of chemotherapy.
Papers referring to symptoms during
chemotherapy without specifying the time
point (such as which cycle) were not considered
for analysis.
Statistical Analyses
A database was developed using IBM SPSS
Statistics software (version 23.0 for Mac; IBM
Corp., Armonk, NY, USA). Frequencies and
descriptive statistics were examined for each
variable. The primary outcome of interest was
the proportion of patients who experienced
pain because of PIPN.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
Search Results
This search strategy resulted in the identifica-
tion of 353 articles. A total of 282 articles were
excluded during the eligibility assessment, and
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25 additional papers were identified by scan-
ning the reference lists. Therefore, 96 papers
met the inclusion criteria and were used for this
review [9–104]. These studies were published
between 1980 and 2017. Figure 1 illustrates the
study selection process.
Full clinical and neurophysiological data
were further extracted from 54 papers [29–82]
involving a total of 8159 patients (49.8% male)
who received chemotherapy that included pla-
tins. The age of the patients ranged from 18 to
85 years (mean 65.9 years). The demographic
and clinical characteristics of these patients are
summarized in Table 1.
Forty-six papers provided data for the
prevalence of PN in patients who received pla-
tins in their chemotherapeutic scheme. Of
these, 22 papers reported PN during
chemotherapy, 14 reported PN after completion
of chemotherapy, and three specifically repor-
ted the acute toxic effects of oxaliplatin. Seven
papers did not clearly specify the time point
where PN occurred. The prevalence of estab-
lished PN after chemotherapy was estimated at
56.5%.
In 16 studies, patients received only platins,
not combined with another neurotoxic
chemotherapeutic agent. Of these, four papers
Fig. 1 PRISMA chart
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reported PN during chemotherapy, eight
reported PN after completion of chemotherapy,
and three specifically reported the acute toxic
effects of oxaliplatin. One paper did not clearly
specify the time point at which PN occurred.
The prevalence of neuropathic symptoms due
to acute toxicity of oxaliplatin was estimated at
84.6%, whereas established PN after
chemotherapy with platins was estimated at
74.9%. Of note, in only two studies—which
provided data about the prevalence of PIPN—
was PN confirmed with a full neurophysiologi-
cal assessment.
Specifically regarding pain, the reported
prevalence of pain due to acute toxicity of
oxaliplatin was estimated at 55.6%, whereas the
reported prevalence of chronic peripheral neu-
ropathic pain in PIPN was estimated at 49.2%.
Epidemiological Characteristics of PIPN
Ameta-analysis of 31 studies providing data from
4179 patients established that the prevalence of
CIPN was 68.1% (95% CI 57.7–78.4%) when
measured in the first month after chemotherapy
completion, 60.0% (95% CI 36.4–81.6%) at
3 months, and 30.0% (95% CI 6.4–53.5%) at
6 months ormore [9].However, these figures refer
to a variety of chemotherapeutic agents. More-
over, the diagnosis of the neuropathy was not
made via nerve conduction studies (NCS) in all
cases; in some studies, neuropathywas based only
on quantitative sensory testing (QST), neurologi-
cal examination, and/or questionnaires [9].
Among only those studies in which NCS or QST
was used for assessment of neuropathy, the
prevalence of CIPN was higher: 73.3% (95% CI
58.6–87.3) within 1 month of chemotherapy
cessation, 70.1% (95%CI 41.8–98.4) at 3 months,
and 39.9% (95% CI 3.9–76.0) at 6 months or
greater. A limitation of these figures, however, is
that abnormal results obtained by QST without
having performed NCS does not definitively
establish the presence of PN, and thus the
above-mentioned percentages reflect the pres-
ence of neuropathic symptoms rather than CIPN.
Specificallyconcerningplatins, the incidenceof
neuropathic symptoms for cisplatin ranged from
49% to 100%,whereas carboplatinwas reported to
be less neurotoxic, with neuropathic symptoms
observed in 13% to 42% of cases [10, 11]. The
presence of acute oxaliplatin-induced neuropathic
symptoms has been reported in 85–95% of
patients, and these symptoms have been observed
in a chronic persistent form in approximately
16–21% of patients [11, 12, 56].
Risk Factors for PIPN
Several risk factors have been associated with the
development of painful PIPN. Wang et al. [32]
reported that female sex, patient’s level of
functioning (assessed by the Eastern Cooperative
Oncology Group performance status scale), body
mass index (BMI), and baseline opioid use
were associated with increased severity of
oxaliplatin-induced peripheral neuropathy [32].
Attal et al. [58] revealed a significant relationship
between the severity of acute signs and symptoms
of oxaliplatin neurotoxicity after three cycles of
chemotherapy and the occurrence and severity of
chronic residual neuropathic symptoms as asses-
sed by QST and the Neuropathic Pain Symptom
Inventory (NPSI) after 1 year.
Table 1 Description of studies included in the review
Parameter Value
Number of papers* 54
Total number of patients 8159
Number of patients per study, mean (SD) 151.1 (419.6)
Male: Female 1:1
Mean age, in years 65.9
Diagnosis of PN
Questionnaires only (%) 12 (22.2)
Nerve conduction studies (%) 3 (5.6)
Quantitative sensory testing (%) 7 (13.0)
Clinical examination (%) 8 (14.8)
Not reported (%) 24 (44.4)
Platin-induced PN (%) 73.3
Painful PIPN (%) 45.8
*Providing full clinical and neurophysiological data
SD standard deviation, PN peripheral neuropathy
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Moreover, the duration of neuropathic
symptoms was observed to increase as the
cumulative dose of platin increased [69]. For
example, Leonard et al. found that after the first
cycle of chemotherapy, the median duration of
dysesthesia was only 5 days, whereas it was
21 days in patients who received 12 cycles of
chemotherapy. The median duration of pares-
thesia after cycle 1 was 7 days, but after cycle 12
was 21 days or longer [69]. Similarly, in many
clinical trials sensory symptoms causing func-
tional impairment have been found in only
about 15% of patients after a cumulative dose of
780–850 mg/m2 but in 50% of patients at a
cumulative dose of 1170 mg/m2 [13, 14].
Specifically concerning carboplatin, Take-
moto et al. [88] observed a greater visual ana-
logue scale (VAS) score when it was combined
with paclitaxel than with docetaxel; addition-
ally, as the number of chemotherapy cycles
increased, the carboplatin–paclitaxel-induced
neuropathic symptoms became more severe.
Concerning cisplatin, Bezjak et al. [95]
demonstrated that in lung cancer survivors,
sensory cisplatin-induced neuropathic symp-
toms were a late effect of cisplatin, persisting for
at least 9 months after chemotherapy and
affecting quality of life. Similar symptoms have
been reported as a late effect of cisplatin in
long-term survivors of testicular cancer, and the
cumulative dose of cisplatin has been reported
to be a major risk factor for the development of
toxicity [28].
Not all studies reported screening for
pre-existing neuropathy prior to chemotherapy
with platins. Also, not all studies reported hav-
ing excluded patients with other common risk
factors for PN such as diabetes, excessive alco-
hol intake, gluten sensitivity [105, 106], or
hereditary neuropathies. Therefore, such
comorbidities may have contributed to the
development of PN.
Predictors of PIPN
Cold allodynia and hyperalgesia of the hands
after three cycles of oxaliplatin treatment was
found to be predictive of severe chronic neu-
ropathy [58]. Among a range of cold stimuli,
pain induced by a 20 C stimulus to the hand
had the highest predictive value with regard to
development of severe chronic neuropathy. The
severity of chronic neuropathy was also found
to correlate with the duration of cold-evoked
symptoms, the intensity of acute neuropathic
symptoms, and the intensity of cold-evoked
pain [58].
Management
Management of platin induced peripheral neu-
ropathic pain includes pharmacological and
non-pharmacological approaches [8].
Antidepressants
Venlafaxine, a serotonin and norepinephrine
reuptake inhibitor, was effective in the man-
agement of acute neuropathic symptoms in a
small series of patients receiving oxaliplatin
[100]. Venlafaxine also showed promising pre-
liminary evidence of clinical effectiveness of
this combination against chronic neuropathic
symptoms in oxaliplatin-induced PN [97].
According to the EFFOX study, complete relief
of neuropathic symptoms induced by oxali-
platin was achieved in 31.3% of patients, which
is a significantly higher percentage than the
5.3% achieved with placebo [91].
Duloxetine, another serotonin and nore-
pinephrine reuptake inhibitor, was also found
to be effective in oxaliplatin-induced painful
neuropathy [55]. In an open-label study, Yang
et al. demonstrated that duloxetine could be
used effectively in low doses (i.e. 60 mg/day)
without impairment of renal or liver function—
and importantly, without interfering with
chemotherapy [55]. More recently, a large
placebo-controlled randomized clinical trial
showed that duloxetine was more effective than
placebo in reducing the average PIPN pain score
after a 5-week treatment period [101]. Overall,
duloxetine has the largest volume of evidence
supporting its use in the treatment of painful
PIPN [107].
Nortriptyline, a tricyclic antidepressant,
failed to demonstrate effectiveness for treating
paresthesia or pain in cisplatin-induced neuro-
pathic symptoms [98].
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Anticonvulsants
Topiramate showed promising preliminary evi-
dence of clinical effectiveness of this combina-
tion against chronic neuropathic symptoms in
oxaliplatin-induced PN [97].
Carbamazepine, on the other hand, does not
appear to be beneficial against acute oxali-
platin-induced painful neurotoxicity [99].
Research findings regarding the effectiveness
of gabapentin for treating pain caused by PIPN
remain controversial. In a phase III randomized,
double-blind, placebo-controlled crossover trial,
Rao et al. concluded that gabapentin failed to
demonstrate any benefit [102], whereas an
open-label study by Tsavaris et al. found that
gabapentin monotherapy seemed to be well
tolerated and useful for the management of
chemotherapy-induced neuropathic pain [103].
However, both studies included patients with
PN secondary to other chemotherapeutic agents
in addition to platins. To date, no study has
explored the efficacy of gabapentin alone in
patients with PIPN.
Opioids
Liu et al. [89] reported that tramadol in com-
bination with acetaminophen, administered
in patients with colorectal or gastric adeno-
carcinoma, was effective in relieving oxali-
platin-induced peripheral neuropathic pain
[89]. Interestingly, this study proposed that
the A118G polymorphism of the mu-opioid
receptor gene (OPRM1) was a possible mech-
anism for the reduced response to the combi-
nation of tramadol and acetaminophen [89],
suggesting that management should be always
be tailored to individual patient
characteristics.
Topical Drugs
In an open-label study, Filipczak-Bryniarska
et al. demonstrated that the high-dose cap-
saicin patch was effective in treating pain
associated with oxaliplatin-induced neuropa-
thy [104]. However, this finding should be
interpreted with caution, given the limitations of
the study design and small number of the
participants.
Non-Pharmacological Approaches
There is some evidence that acupuncture may
be beneficial for the treatment of PIPN. In a
small case series, Donald et al. [87] reported that
patients with oxaliplatin-induced painful neu-
ropathy improved after acupuncture. Wong
et al. [96] similarly described a small series of
patients with symptoms of pain due to carbo-
platin-induced neuropathy who improved after
acupuncture. A prospective pilot study by Hsieh
et al. [30] showed that laser acupuncture
relieved both cold and mechanical allodynia
induced by oxaliplatin in gastrointestinal can-
cer survivors. To date, however, no large ran-
domized controlled trial has been conducted to
confirm the effectiveness of acupuncture in
managing pain in PIPN. Therefore, the current
evidence is weak.
Cunningham et al. [90] reported a case of
almost complete resolution of the tingling,
numbness, and pain of cisplatin-induced neu-
ropathy with manual therapy (massage) in a
patient with stage III esophageal adenocarci-
noma. However, as this was based on a single
case, this finding should be interpreted with
extreme caution.
Henke et al. [84] reported that strength and
endurance training in patients receiving plat-
inum-based chemotherapy for lung cancer was
effective in managing pain. The authors thus
suggested that lung cancer patients should
receive enhanced physical activity intervention
during palliative chemotherapy.
Diagnosing and Monitoring PIPN
Large Fiber Neuropathy
The gold standard for diagnosing a large fiber
neuropathy is NCS. Although centers have
many different means of neurophysiologically
determining the presence of PN, sensory con-
duction studies of sural and radial nerves are
recommended for the diagnosis of mild, pre-
dominantly sensory axonal neuropathy [108].
This should be complemented with at least one
motor study, commonly of the tibial nerve, to
confirm motor involvement [109, 110]. In the
case of PIPN, however, the neuropathy is sen-
sory, affecting the dorsal root ganglia. In a
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sensory ganglionopathy, asymmetrical sensory
nerve action potentials (SNAPs) or complete
absence of SNAPs should be expected [111, 112].
Small Fiber Neuropathy
Patients often complain of disabling symptoms
such as a burning sensation in the soles or the
fingertips, which is a common manifestation of
small fiber neuropathy (SFN). Nerve conduction
studies assess only large fibers, and therefore,
SFN cannot be excluded if NCS are normal.
The gold standard for a diagnosis of SFN is
skin biopsy; however, this is an invasive tech-
nique and is thus usually avoided. QST is com-
monly used for assessment of SFN, but this is
subjective. Alternatively, nerve morphology can
be rapidly assessed using in vivo corneal con-
focal microscopy. This technique has been used
for the detection of various types of neuropa-
thy, including small fiber neuropathy [15]. Fer-
dousi et al. [35] showed that corneal confocal
microscopy was effective in detecting small
fiber neuropathy by a marked reduction in
corneal nerve morphological parameters in
patients with upper gastrointestinal cancer and
oxaliplatin- or cisplatin-induced neuropathy.
Questionnaires
Several questionnaires have been used for the
detection and assessment of PIPN. Particular
interest has been focused on the development
and validation of questionnaires regarding
quality of life in patients with CIPN.
The European Organisation for Research and
Treatment of Cancer Quality of Life Question-
naire C30 (EORTC QLQ-C30), designed to assess
quality of life for cancer patients, is widely used
and consists of 30 items comprising five func-
tional scales (physical, role, emotional, cogni-
tive, and social), global health status, and nine
symptom scales and single items (fatigue, nau-
sea and vomiting, pain, dyspnea, insomnia,
appetite loss, constipation, diarrhea, and
financial difficulties. It is also supplemented
with specific modules for the different cancer
types [16, 17, 83, 84, 95].
The EORTC QLQ-CIPN20 is a quality-of-life
questionnaire developed to elicit patient expe-
rience of symptoms and functional limitations
related to CIPN. It contains 20 items assessing
sensory, motor, and autonomic symptoms
[18, 86]. The CIPN20 can assess frequency and
severity of painful CIPN in a wide range of
oncology patient populations.
The L-BASIC [location-based assessment of
sensory symptoms in cancer] instrument uses
location-specific ratings of sensory symptoms in
the cancer population [94]. It is structured such
that patients provide a numeric score and an
adjectival description for any sensory symp-
toms, including both pain and neuropathic
sensations, present in each of 10 predefined
body areas [94].
The Rasch-built Overall Disability Scale for
CIPN (CIPN-R-ODS) is a Rasch-built dis-
ease-specific interval measure suitable for
detecting disability and levels of activity and
participation in patients with stable disease
[85].
She Functional Assessment of Cancer Ther-
apy/Gynecologic Oncology Group-Neurotoxic-
ity (FACT/GOG-Ntx) questionnaire is the
Functional Assessment of Cancer Ther-
apy-General (FACT-G) instrument plus an 11--
item subscale (Ntx subscale) [19]. It is a
chemotherapy treatment effect-specific mea-
surement tool used to evaluate the severity and
impact of CIPN symptoms on functional status
and health-related quality of life [19]. Questions
on the Ntx subscale include the feeling of gen-
eralized weakness, numbness or tingling in the
hands or feet, and difficulty with fine motor
movements [19, 20].
The Total Neuropathy Score (TNS) was ini-
tially designed to evaluate diabetic neuropathy
[21] and was later validated in patients with
CIPN [22]. The TNS includes objective mea-
sures, such as pin prick, vibration threshold,
and nerve conduction studies, combined with
subjective report of sensory, motor, and auto-
nomic items, and the instrument has been tes-
ted in a variety of tumor types [22–24, 93].
The chemotherapy-induced neuropa-
thy-specific Neuropathic Pain Scale (NPS-CIN) is
a six-item scale used to assess CIPN and related
neuropathic pain severity [25, 92, 93].
The Patient Neurotoxicity Questionnaire,
comprising two items, defines the incidence
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and severity of sensory and motor disturbances
[26].
The Chemotherapy-Induced Peripheral
Neuropathy Assessment Tool (CIPNAT) con-
tains 36 items that evaluate the occurrence,
severity, distress, and frequency of nine neuro-
pathic symptoms, along with 14 items that
evaluate neuropathic interference with activi-
ties [27].
CONCLUSION
This systematic review has identified the fol-
lowing key points:
1. PN is a common complication in patients
receiving platins in their chemotherapeutic
regime.
2. PIPN can be particularly painful. Acute
toxicity occurs only with oxaliplatin. How-
ever, in a significant proportion of patients
receiving platins, the pain persists and
becomes chronic.
3. There is significant heterogeneity in the
methods used to diagnose PN. In many
studies, patients were diagnosed based only
on questionnaires or clinical examination.
Although the use of questionnaires may be
adequate for characterizing and monitoring
neuropathic symptoms, the gold standard
for accurate diagnosis of an established
peripheral neuropathy—from a neurologi-
cal point of view—is NCS. Ideally, this
should be performed as a baseline, before
the chemotherapy, and should be repeated
at the end or when symptoms occur. QST
alone is not sufficient for establishing a
diagnosis of PN, as it is not objective, and its
role is more as an indicator of small fiber
involvement; therefore, QST should be
complemented with NCS.
4. Small fiber neuropathy is gaining increasing
attention in clinical practice; however, fur-
ther studies are needed in patients receiving
platins, as the neuropathic pain that
patients experience during chemotherapy
with platins is likely often secondary to
small fiber involvement, with no involve-
ment of the large fibers.
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